A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

Inclusion Criteria

• •Male with ≥ 1 diagnosis claim for prostate cancer
• •Had documented secondary metastasis code on or after the initial prostate cancer diagnosis
• •Had initiated novel hormonal therapy (abiraterone, apalutamide, or enzalutamide) within 90 days prior to the metastasis date or on or after the metastasis date. The initiation date of the earliest novel hormonal therapy will be defined as the index date
• •≥18 years old on index date
• •Continuous enrollment for at least 365 days before index date
• •Evidence to be castration-sensitive:
• •* No prior surgical castration any time prior to the index date or no medical castration with ≥8 weeks of continuous use within -90 to -365 days prior to the index date, OR
• •* Diagnosis of hormone sensitive malignancy status within 90 days before the index date